Clinical Trial

Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This study is a randomized, prospective, comparative study of the effectiveness of prophylactic entecavir treatment for HBV reactivation in past HBV infected patients (HBsAg-, HBcIgG+) with allogeneic hematopoietic stem cell transplantation.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-06-20; most recent amendment 2025-07-15.
Status change: Recruiting → Enrolling by Invitation 2022-12-16
Trial Details
NCT Number NCT04942886
Lead Sponsor Seoul St. Mary's Hospital
Conditions Hepatitis B Reactivation, Hematopoietic Stem Cell Transplantation, Antiviral Drug, HBV
Enrollment 226 participants
Start Date 2021-08-21
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-18